ZIVO Bioscience (ZIVO) Competitors $11.05 -0.16 (-1.43%) As of 11:25 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ZIVO vs. FDMT, ENGN, YMAB, OGI, CRBU, DMAC, RAPT, SXTC, GNFT, and CTMXShould you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include 4D Molecular Therapeutics (FDMT), enGene (ENGN), Y-mAbs Therapeutics (YMAB), Organigram Global (OGI), Caribou Biosciences (CRBU), DiaMedica Therapeutics (DMAC), Rapt Therapeutics (RAPT), China SXT Pharmaceuticals (SXTC), GENFIT (GNFT), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. ZIVO Bioscience vs. Its Competitors 4D Molecular Therapeutics enGene Y-mAbs Therapeutics Organigram Global Caribou Biosciences DiaMedica Therapeutics Rapt Therapeutics China SXT Pharmaceuticals GENFIT CytomX Therapeutics 4D Molecular Therapeutics (NASDAQ:FDMT) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Which has more volatility & risk, FDMT or ZIVO? 4D Molecular Therapeutics has a beta of 2.81, meaning that its share price is 181% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Does the media prefer FDMT or ZIVO? In the previous week, 4D Molecular Therapeutics had 5 more articles in the media than ZIVO Bioscience. MarketBeat recorded 5 mentions for 4D Molecular Therapeutics and 0 mentions for ZIVO Bioscience. 4D Molecular Therapeutics' average media sentiment score of 0.65 beat ZIVO Bioscience's score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Overall Sentiment 4D Molecular Therapeutics Positive ZIVO Bioscience Neutral Is FDMT or ZIVO more profitable? ZIVO Bioscience has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. ZIVO Bioscience's return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular Therapeutics-767,126.06% -33.26% -30.68% ZIVO Bioscience N/A N/A -2,240.92% Do institutionals & insiders have more ownership in FDMT or ZIVO? 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation & earnings, FDMT or ZIVO? ZIVO Bioscience has lower revenue, but higher earnings than 4D Molecular Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$40K5,293.20-$160.87M-$3.18-1.44ZIVO Bioscience$15.85K2,661.06-$7.78M-$4.93-2.24 Do analysts rate FDMT or ZIVO? 4D Molecular Therapeutics presently has a consensus target price of $29.56, suggesting a potential upside of 546.73%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than ZIVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Summary4D Molecular Therapeutics beats ZIVO Bioscience on 12 of the 16 factors compared between the two stocks. Get ZIVO Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIVO vs. The Competition Export to ExcelMetricZIVO BioscienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.18M$273.51M$5.70B$9.51BDividend YieldN/AN/A4.69%4.01%P/E Ratio-2.26N/A28.0720.05Price / Sales2,661.06364.38448.5799.42Price / CashN/A22.4436.2258.56Price / Book-13.6412.418.665.87Net Income-$7.78M-$106.40M$3.25B$258.55M7 Day Performance-16.60%4.86%4.20%2.23%1 Month Performance-25.89%25.43%10.82%12.76%1 Year Performance30.15%11.08%34.70%19.36% ZIVO Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIVOZIVO BioscienceN/A$11.05-1.4%N/A+32.6%$42.18M$15.85K-2.2610FDMT4D Molecular Therapeutics2.3893 of 5 stars$4.37+3.1%$29.56+576.3%-74.3%$200.89M$40K-1.36120ENGNenGene2.8484 of 5 stars$3.93+1.9%$23.29+493.3%-57.3%$200.84MN/A-2.3831YMABY-mAbs Therapeutics3.6469 of 5 stars$4.42+2.0%$15.60+253.3%-60.9%$197.87M$87.68M-6.83150News CoveragePositive NewsOGIOrganigram Global1.3259 of 5 stars$1.50+2.4%N/A-7.1%$197.56M$117.47M14.75860CRBUCaribou Biosciences2.9566 of 5 stars$2.12+2.5%$8.50+300.8%+4.9%$195.86M$9.99M-1.30100News CoverageDMACDiaMedica Therapeutics1.4853 of 5 stars$4.56+0.3%$10.75+136.0%+33.7%$194.69MN/A-7.0920News CoverageInsider TradeRAPTRapt Therapeutics4.3528 of 5 stars$11.72+0.2%$19.80+68.9%-50.0%$193.85M$1.53M-0.6180Analyst UpgradeAnalyst RevisionSXTCChina SXT Pharmaceuticals1.2378 of 5 stars$1.64+0.7%N/A-82.2%$192.61M$1.82M0.0090Positive NewsGap UpGNFTGENFIT2.4865 of 5 stars$3.83-1.9%$13.00+239.9%-4.0%$191.26M$67.00M0.00120Gap DownCTMXCytomX Therapeutics4.2271 of 5 stars$2.36-1.1%$5.33+126.5%+70.7%$189.86M$147.56M4.91170News CoveragePositive NewsGap Up Related Companies and Tools Related Companies FDMT Alternatives ENGN Alternatives YMAB Alternatives OGI Alternatives CRBU Alternatives DMAC Alternatives RAPT Alternatives SXTC Alternatives GNFT Alternatives CTMX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIVO) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
